Business Wire

WA-EKATA

7.4.2021 15:02:11 CEST | Business Wire | Press release

Share
Ekata Launches Merchant Onboarding Solution to Enable Faster, Smarter Assessments of Merchant Risk

Ekata , the leader in global digital identity data, today announced its Merchant Onboarding solution to help payment service providers (PSPs), B2B lenders and marketplaces onboard the growing number of micro-merchants and sole proprietors across the globe faster and with more confidence. The lack of commercial track record for these new small businesses makes it difficult for PSPs and lenders to quickly and confidently approve them using traditional methods of risk assessment. Ekata set out to help customers enhance their existing models with risk indicators that show fraud likelihood based on a mix of comprehensive customer data tests and best-practice considerations. By providing unique data that cross-checks the connection between businesses and the individuals behind them, Ekata’s new merchant onboarding solution enables organizations to confidently assess risk at scale, automate onboarding workflows, and reduce time spent in manual review.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005320/en/

The global pandemic accelerated an existing trend of individuals establishing their own small businesses. In the U.S. alone there are 30 million small merchants and an additional 40 million individuals who became independent contractors in 2020. Similarly, Europe has 25.1 million small businesses and a growing 33 million sole proprietors . On the tailwinds of this trend, Covid-19 added some additional unexpected fuel: in October 2020, the U.S. Census Bureau published the business-formation statistics for the third quarter of 2020. Third-quarter 2020 business applications rose by 77.4% from June to September .

With this massive growth comes an increasing demand for quick and effective onboarding of these merchants by PSPs and lending institutions. Companies like Stripe, Square, PayPal and others have set a new standard by cutting onboarding times from 2-3 days to just minutes, often threatening the business viability of other PSPs whose processes and risk assessments can’t keep up with their pace. In this intensely competitive market, Ekata’s solution helps PSPs and lenders respond to the increasing expectations for speedier onboarding.

Merchants today have plenty of options and will quickly turn to another payment service provider if an organization adds too much friction at onboarding or takes too long on approvals ,” says Beth Shulkin, Ekata’s VP of Global Marketing. “This is much more than a customer experience issue for PSPs and lenders; losing the lifetime value of a merchant has real bottom-line impact .”

Ekata’s holistic solution is designed to solve both sides of the flow: automating the onboarding process via APIs and enabling more efficient manual reviews with a SaaS solution. Our API integrates easily with existing rules or machine learning-based risk models, and our SaaS product quickly surfaces correlations between key individual and business identity attributes on easy-to-read dashboards.

Key benefits of the Merchant Onboarding solution include:

  • Onboard micro-merchants and sole proprietor businesses with higher confidence: With individual, business, and unique cross-linked signals, Ekata customers can build trusted risk profiles for micro-merchants and sole proprietors that lack the typical track record - verifying information and approving or rejecting applications with confidence.
  • Quickly route good customers for automated underwriting: Businesses can shift low-risk merchant applications away from high friction onboarding steps such as supplemental document collection and manual review, towards automated approval, which gets these customers onboard and generating revenue as quickly as possible. They can then focus on high-risk customers that need additional documentation or manual review.
  • Reduce time spent in manual review: Businesses can quickly view a key set of individual and business data, reducing the time needed to research data across multiple sources and helping the reviewer make a faster, more efficient, and more accurate decision.

For additional information on Ekata’s Merchant Onboarding API, visit here . To learn more about Ekata’s Merchant Review, visit here .

About Ekata

Ekata provides global identity verification via APIs and a SaaS solution to provide businesses worldwide the ability to link any digital transaction to the human behind it. The Ekata product suite is powered by the Ekata Identity Engine, our proprietary, intellectual property, that uses unique datasets from the Ekata Identity Graph and the Ekata Identity Network that provides identity verification data with consistent results across the globe, in industry-leading response times, to enable businesses around the world like AliPay, Microsoft, Stripe, and Airbnb to fight fraud, reduce false declines, and make accurate risk decisions about their customers faster than the blink of an eye.

Ekata is a trademark of Ekata, Inc. All other trade names, trademarks and registered trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye